-

InterVenn Biosciences to Present at the Bank of America 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, Co-Founder and CEO, will present at the Bank of America 2022 Healthcare Conference on Tuesday, May 10, 2022 in Las Vegas, NV.

Bank of America 2022 Healthcare Conference
Date: Tuesday, May 10, 2022
Time: 2:00pm PT / 5:00pm ET
Location: Las Vegas, NV
Format: Formal presentation and 1x1s

A live webcast of the event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/. A replay will be available for 90 days following the event.

About InterVenn Biosciences

InterVenn is a clinical technology company leveraging AI-powered software to unlock the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode and unlock the potential of the glycoproteome at clinically meaningful scale for the first time in history. To optimize this entirely new dimension of biology, the company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening, to diagnostics, and potentially therapeutics. InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.

Contacts

Investor Contact
David Deuchler, CFA
Gilmartin Group
ir@venn.bio

InterVenn Biosciences


Release Versions

Contacts

Investor Contact
David Deuchler, CFA
Gilmartin Group
ir@venn.bio

More News From InterVenn Biosciences

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, the life science company pioneering glycoproteomics co-founded by Nobel Prize winner Carolyn Bertozzi, PhD, Carlito Lebrilla, Ph.D., and Aldo Carrascoso, today announced changes to its senior management team to support its commercialization execution. Erwin Estigarribia, previously InterVenn’s President and Chief Operating Officer, has been appointed as Chief Executive Officer. Laura Beggrow, a commercial-stage business leader...

InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, a life science company pioneering glycoproteomics to improve human health, today announced that senior management will present at the J.P. Morgan 41st annual Healthcare Conference on January 11, 2023 at 8:30 a.m. Pacific. InterVenn’s management team will be available for one-on-one meetings with investors, analysts and other interested parties during the conference. About InterVenn Biosciences InterVenn is a clinical technolog...

InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time. The members of InterVenn’s executive leadership team will be available for one-on-one meetings at the event. A live and archived webcast of...
Back to Newsroom